Summary & Overview
HCPCS U0004: SARS-CoV-2 High-Throughput Multiplex Molecular Test
HCPCS Level II code U0004 designates a high-throughput molecular test for SARS-CoV-2 that detects multiple targets or subtypes and is performed by non-CDC laboratories. This code became nationally relevant during the COVID-19 public health response as payers and providers adopted new testing codes to support large-volume diagnostic capacity. It matters nationally because it standardizes reporting and billing for multiplex, high-throughput assays critical for pandemic surveillance, case identification, and public health response.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical context, typical sites of service, payer coverage patterns, and where this code fits in laboratory service lines. The publication summarizes policy updates tied to COVID-19 testing code implementation, national implications for testing capacity and billing workflows, and operational benchmarks where available. Data not provided in the input are noted explicitly in the sections that require them.
Billing Code Overview
HCPCS Level II code U0004 describes a SARS-CoV-2 (COVID-19) test using high-throughput technologies that detect multiple targets or subtypes, performed by non-CDC laboratories. The description specifies testing for 2019-nCoV coronavirus, SARS-CoV-2/2019-nCoV, using any technique designed to detect multiple types or subtypes and that includes all targets as outlined in CMS guidance (cms-2020-01-r).
Service Type: High-throughput molecular diagnostic testing for SARS-CoV-2.
Typical Site of Service: Clinical laboratories and high-complexity laboratory facilities capable of high-throughput molecular testing.
Clinical & Coding Specifications
Clinical Context
A symptomatic adult presents to a high-throughput clinical laboratory or hospital outpatient testing site with fever, cough, and recent exposure to a confirmed SARS-CoV-2 case. A nasopharyngeal or anterior nasal swab is collected using facility protocols. The specimen is received in a certified molecular laboratory that runs non-CDC high-throughput SARS-CoV-2 assays capable of detecting multiple viral targets or subtypes. The laboratory performs automated extraction and amplification on high-throughput platforms and reports a qualitative positive or negative result. Typical workflow steps include specimen accessioning, barcode scanning, nucleic acid extraction, amplification and detection using the laboratory’s validated assay, result verification by a molecular technologist, and electronic reporting to the ordering clinician and public health authorities as required. Billing is submitted under U0004 for specimens processed using these non-CDC high-throughput methods. Common settings include hospital laboratories, independent reference labs, and large outpatient collection centers equipped for batch molecular testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Service performed by the physician or other qualified health care professional | When the billing provider performed professional duties associated with test ordering review or interpretation as allowed |
26 | Professional component | When billing separate professional interpretation or review of laboratory results apart from technical testing |
TC | Technical component | When billing for the laboratory technical processing only (instrumentation, reagents, personnel) |
QX | Registered nurse or physician assistant service furnished under supervision of a physician | When an authorized mid-level clinician provided specimen collection under physician supervision and payer requires modifier |
QY | Patient provided services in whole or part by another institution per arrangement | When testing performed under an arrangement where another entity supplied the testing platform or personnel |
CQ | Service furnished as part of a clinical research study | Use when the test was performed as part of a clinical trial and payer requires research modifier |
SH | Service performed in a skilled nursing facility | When specimen collection or testing is provided while patient is a resident of a skilled nursing facility |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services furnished in whole or part under general supervision | When an advanced practice clinician performed specimen collection and supervision rules require modifier |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure for a related procedure during the postoperative period | Rarely applicable; use only if test-guided procedure required immediate return to OR for a related intervention |
62 | Two surgeons | When two qualified providers share responsibility for a complex procedure where intraoperative testing affected management |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 362Y00000X | Laboratory Director | Physicians who direct molecular diagnostic laboratories and oversee testing quality |
| 207Q00000X | Infectious Disease | Specialists ordering and interpreting complex SARS-CoV-2 molecular testing for patient management |
| 207L00000X | Pathology | Pathologists involved in validation, oversight, and interpretation of molecular assays |
| 163W00000X | Clinical Laboratory | Clinical laboratory scientists and managers performing high-throughput testing operations |
| 367A00000X | Public Health Laboratory | Public health laboratory professionals coordinating reporting and surveillance activities |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
J12.82 | Pneumonia due to coronavirus disease 2019 | Indicates lower respiratory tract infection from SARS-CoV-2 where molecular testing confirms diagnosis |
U07.1 | COVID-19 | Primary diagnosis for confirmed SARS-CoV-2 infection; justifies diagnostic molecular testing using U0004 |
R05 | Cough | Symptom prompting SARS-CoV-2 testing in outpatient or emergency evaluation |
R50.9 | Fever, unspecified | Common presenting sign that supports diagnostic testing for SARS-CoV-2 |
Z20.828 | Contact with and (suspected) exposure to other viral communicable diseases | Reason for testing asymptomatic or exposed individuals using high-throughput assays |
J00 | Acute nasopharyngitis [common cold] | Differential diagnosis when respiratory symptoms overlap; testing distinguishes SARS-CoV-2 from other viral etiologies |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
87635 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique | Commonly used alternative CPT for SARS-CoV-2 molecular testing when reporting per specimen for single-target assays; may appear on claims alongside or instead of HCPCS depending on payer rules |
87636 | Infectious agent detection by nucleic acid (DNA or RNA); multiple organisms (multiplex), respiratory panel | Performed when multiplex respiratory pathogen panels including SARS-CoV-2 are ordered; workflow may include reflex to U0004 high-throughput methods for batch processing |
0003U | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant sequencing, multiplexed, whole genome or targeted, high throughput | Used when sequencing is performed following a positive U0004 result for variant surveillance; represents downstream specialized testing |
99000 | Handling and/or conveyance of specimen for transport to a laboratory | Used by some facilities to bill specimen handling/transport steps in complex workflows involving off-site high-throughput labs |
99001 | Handling and/or conveyance of specimen for transport to a laboratory, rural or other specific circumstances | Used in select circumstances for specimen logistics when permitted by payer policies |